



**PLEASE NOTE:** *This trial has been registered retrospectively.*

## Trial Description

### Title

**Epidemiological community acquired pneumonia study**

### Trial Acronym

**CAPNETZ Study**

### URL of the trial

**<http://www.capnetz.de/html/home>**

### Brief Summary in Lay Language

**Long-term objectives of the basic research part are improvement of CAP-management with respect to therapy, diagnosis and prevention.**

### Brief Summary in Scientific Language

**Long-term objectives of the basic research part are improvement of CAP-management with respect to therapy, diagnosis and prevention to contribute to a better care of patients with pneumonia.**

## Organizational Data

- DRKS-ID: **DRKS00005274**
- Date of Registration in DRKS: **2013/09/11**
- Date of Registration in Partner Registry or other Primary Registry: [---]\*
- Investigator Sponsored/Initiated Trial (IST/IIT): **yes**
- Ethics Approval/Approval of the Ethics Committee: **Approved**
- (leading) Ethics Committee Nr.: **104/01 , Ethikkommission der Medizinischen Fakultät der Otto-von-Guericke-Universität Magdeburg**

## Secondary IDs

- Universal Trial Number (UTN): **U1111-1147-8393**

## Health condition or Problem studied

- Free text: **CAP; Community Acquired Pneumonia; ambulant erworbenen Pneumonie;**
- ICD10: **J18 - Pneumonia, organism unspecified**

## Interventions/Observational Groups

- Arm 1: **Long-term objectives of the basic research part are improvement of CAP-management with respect to therapy, diagnosis and prevention to contribute to a better care of patients with pneumonia**

## Characteristics

- Study Type: **Non-interventional**
- Study Type Non-Interventional: **Epidemiological study**
- Allocation: **Single arm study**
- Blinding: [---]\*
- Who is blinded: [---]\*
- Control: **Uncontrolled/Single arm**
- Purpose: **Treatment**
- Assignment: **Single (group)**
- Phase: **N/A**
- Off-label use (Zulassungsüberschreitende Anwendung eines Arzneimittels): **N/A**

## Primary Outcome

**Long-term objectives are improvement of CAP-management with respect to therapy, diagnosis and prevention**

## Secondary Outcome

**to contribute to a better care of patients with pneumonia**

## Countries of recruitment

- DE **Germany**
- NL **Netherlands**
- CH **Switzerland**
- DK **Denmark**

## Locations of Recruitment



- University Medical Center **CAPNETZ STIFTUNG, Hannover**

## Recruitment

- Planned/Actual: **Actual**
- (Anticipated or Actual) Date of First Enrollment: **2002/10/01**
- Target Sample Size: **10000**
- Monocenter/Multicenter trial: **Multicenter trial**
- National/International: **International**

## Inclusion Criteria

- Gender: **Both, male and female**
- Minimum Age: **18 Years**
- Maximum Age: **no maximum age**

## Additional Inclusion Criteria

**age ≥ 18, infiltrate on chest X-ray, further Inclusion criteria: cough or production of purulent sputum or pathologic lung auscultation (crackles) or fiver**

## Exclusion criteria

**hospital inpatient treatment within the last 28 days, Immune suppressed patients, immunosuppression**

## Addresses

- **Primary Sponsor**

**Universitätsklinikum Ulm, Institut für Medizinische Mikrobiologie und Hygiene  
Albert-Einstein-Allee 23  
89081 Ulm  
Germany**

Telephone: [---]\*

Fax: [---]\*

E-mail: [---]\*

URL: [---]\*

- **Contact for Scientific Queries**

**MUMC+Department of Respiratory Medicine  
Mr. Prof. Dr. Gernot Rohde  
Postbus 5800  
6202 Maastricht**



### **Contact for Scientific Queries**

**MUMC+Department of Respiratory Medicine**

**Mr. Prof. Dr. Gernot Rohde**

**Postbus 5800**

**6202 Maastricht**

**Netherlands**

Telephone: **0031-43387-6372**

Fax: [---]\*

E-mail: **g.rohde at mumc.nl**

URL: [---]\*

### ■ **Contact for Public Queries**

**Universitätsklinikum Jena**

**Mr. Prof. Dr. Mathias Pletz**

**Erlanger Allee 101**

**07743 Jena**

**Germany**

Telephone: **03641 932 4650**

Fax: [---]\*

E-mail: **Mathias.Pletz at med.uni-jena.de**

URL: [---]\*

## **Sources of Monetary or Material Support**

- **Public funding institutions financed by tax money/Government funding body (German Research Foundation (DFG), Federal Ministry of Education and Research (BMBF), etc.)**

**Helmholtz Zentrum München - Deutsches Forschungszentrum für Gesundheit und Umwelt, GmbH**

**Ingolstädter Landstraße 1**

**85764 Neuherberg**

**Germany**

Telephone: [---]\*

Fax: [---]\*

E-mail: [---]\*

URL: [---]\*

## **Status**

- Recruitment Status: **Recruiting ongoing**
- Study Closing (LPLV): [---]\*



## Trial Publications, Results and other documents

- Paper **Presentation, etiology and outcome of pneumonia in younger nursing home residents.**
- Paper **Serum glucose levels for predicting death in patients admitted to hospital for community acquired pneumonia: prospective cohort study.**
- Paper **Serum cortisol predicts death and critical disease independently of CRB-65 score in community-acquired pneumonia: a prospective observational cohort study**
- Paper **Community-acquired pneumonia in younger patients is an entity on its own**
- Paper **Nursing-home-acquired pneumonia in Germany: an 8-year prospective multicentre study**
- Paper **Moxifloxacin monotherapy versus  $\beta$ -lactam mono- or combination therapy in hospitalized patients with community-acquired pneumonia**
- Paper **How deadly is seasonal influenza-associated pneumonia? The German Competence Network for Community-Acquired Pneumonia.**
- Paper **Influenza vaccination is associated with reduced severity of community-acquired pneumonia.**
- Paper **Pro-atrial natriuretic peptide and pro-vasopressin for predicting short-term and long-term survival in community-acquired pneumonia: results from the German Competence Network CAPNETZ.**
- Paper **Cardiovascular and inflammatory biomarkers to predict short- and long-term survival in community-acquired pneumonia: Results from the German Competence Network, CAPNETZ.**
- Paper **Community-acquired pneumonia through Enterobacteriaceae and Pseudomonas aeruginosa: Diagnosis, incidence and predictors**
- Paper **Impact of intravenous {beta}-lactam/macrolide versus {beta}-lactam monotherapy on mortality in hospitalized patients with community-acquired pneumonia.**
- Paper **Mycoplasma pneumoniae pneumonia revisited within the German Competence Network for Community-acquired pneumonia (CAPNETZ).**
- Paper **Outcome of community-acquired pneumonia: influence of age, residence status and antimicrobial treatment.**
- Paper **Procalcitonin predicts patients at low risk of death from community-acquired pneumonia across all CRB-65 classes**
- Paper **Community-acquired Legionella pneumonia: new insights from the German competence network for community acquired pneumonia.**
- Paper **Antibiotic treatment of community acquired pneumonia varies widely across Germany.**
- Paper **Pro-atrial natriuretic peptide and pro-vasopressin to predict severity and prognosis in community-acquired pneumonia: results from the German competence network CAPNETZ**
- Paper **CRB-65 predicts death from community-acquired pneumonia.**

\* This entry means the parameter is not applicable or has not been set.

\*\*\* This entry means that data is not displayed due to insufficient data privacy clearing.